Correct Answer: D. Erythromycin
Erythromycin is the drug of choice for eradicating Corynebacterium diphtheriae from the nasopharynx in carrier states because it achieves superior intracellular and respiratory secretion penetration compared to other agents. In diphtheria carriers (asymptomatic individuals colonized with toxigenic or non-toxigenic strains), the goal is microbiological eradication to prevent transmission, not clinical disease treatment. Erythromycin (500 mg QID for 7 days) reliably clears the organism from the nasopharynx in >90% of carriers, as documented in Indian epidemiological studies and RNTCP guidelines. The macrolide's lipophilic nature allows excellent lung and respiratory epithelial penetration, achieving bactericidal concentrations in respiratory secretions. Rifampicin, though highly effective, is reserved for treatment failures or contacts due to cost and resistance concerns in the Indian setting. Erythromycin remains the standard recommendation in Harrison's and Indian pediatric textbooks (OP Ghai) for carrier eradication, particularly important in India where diphtheria surveillance and contact tracing remain public health priorities under the National Immunization Schedule.
Why the other options are wrong
A. Amoxicillin — Amoxicillin is a β-lactam antibiotic with poor penetration into respiratory secretions and does not achieve adequate bactericidal concentrations in the nasopharynx to reliably eradicate C. diphtheriae carriers. While it may treat acute diphtheria toxemia clinically, it fails as a carrier eradication agent. NBE may trap students who confuse acute disease treatment with carrier state management. B. Tetracycline — Tetracycline has moderate activity against C. diphtheriae but inferior respiratory secretion penetration compared to macrolides. It is not recommended for carrier eradication in Indian guidelines and shows lower microbiological clearance rates. The trap here is that tetracycline is a broad-spectrum agent—students may assume it covers diphtheria, but specificity for carrier eradication is lacking. C. Rifampicin — Although rifampicin is highly bactericidal and penetrates respiratory secretions excellently, it is NOT first-line for routine carrier eradication due to cost, potential for resistance emergence, and hepatotoxicity concerns in the Indian healthcare context. It is reserved for erythromycin-resistant strains or treatment failures. NBE exploits the misconception that 'most effective' equals 'drug of choice.'
High-Yield Facts
- Erythromycin 500 mg QID × 7 days is the standard DOC for C. diphtheriae carrier eradication with >90% microbiological clearance.
- Carrier state is asymptomatic nasopharyngeal colonization; goal is transmission prevention, not toxin neutralization (unlike acute diphtheria which requires antitoxin + antibiotics).
- Rifampicin is reserved for erythromycin-resistant carriers or treatment failures due to cost and resistance risk in Indian settings.
- Respiratory secretion penetration is the critical pharmacokinetic property for carrier eradication; macrolides excel here, β-lactams do not.
- Post-treatment surveillance requires repeat nasopharyngeal swabs at weeks 2 and 4 to confirm eradication per RNTCP guidelines.
Mnemonics
ERYTHRO for Carriers Erythromycin for Eradication of C. diphtheriae carriers. Macrolides penetrate respiratory secretions → nasopharyngeal clearance. Use when you see 'carrier state' + diphtheria. Acute vs Carrier DOC Acute diphtheria = Antitoxin + Penicillin/Cephalosporin (toxin neutralization + systemic coverage). Carrier state = Erythromycin alone (respiratory eradication). Different goals = different drugs.
NBE Trap
NBE pairs rifampicin (the most potent agent) with diphtheria to trap students who equate 'most bactericidal' with 'drug of choice.' The question specifically asks for carrier eradication—a public health/epidemiological context where cost-effectiveness and first-line accessibility matter; rifampicin is reserved for failures.
Clinical Pearl
In Indian public health practice, identifying and treating diphtheria carriers is critical for outbreak prevention, especially in low-immunization pockets. A single course of erythromycin is cost-effective and reliable; rifampicin is reserved for the rare erythromycin-resistant case, making erythromycin the pragmatic first-line choice in resource-limited settings.
_Reference: Harrison Ch. 139 (Diphtheria); OP Ghai Essentials of Pediatrics Ch. 5 (Infectious Diseases); KD Tripathi Pharmacology Ch. 47 (Macrolides)_